Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Bemarituzumab by Amgen for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase I for Squamous Non-Small Cell Lung Cancer. According to...
Bemarituzumab by Amgen for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData,...
Bemarituzumab by Amgen for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
Bemarituzumab by Amgen for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....
Bemarituzumab by Amgen for Epithelial Ovarian Cancer: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...
Bemarituzumab by Amgen for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According...
Bemarituzumab by Amgen for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase III for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData,...
Bemarituzumab by Amgen for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase III for Adenocarcinoma Of The Gastroesophageal Junction. According to...
Bemarituzumab by Amgen for Endometrial Cancer: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...
Bemarituzumab by Amgen for Solid Tumor: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
Bemarituzumab by Amgen for Gastric Cancer: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase III for Gastric Cancer. According to GlobalData, Phase III...
Bemarituzumab by Amgen for Lymphoma: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs...
Bemarituzumab by Amgen for Cervical Cancer: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...
Bemarituzumab by Amgen for Lung Adenocarcinoma: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase II...
Bemarituzumab by Amgen for Peritoneal Cancer: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...
Bemarituzumab by Amgen for Fallopian Tube Cancer: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Amgen's Bemarituzumab?
Bemarituzumab is a monoclonal antibody commercialized by Amgen, with a leading Phase III program in Gastroesophageal (GE) Junction Carcinomas. According...
Risk adjusted net present value: What is the current valuation of Amgen's Bemarituzumab?
Bemarituzumab is a monoclonal antibody commercialized by Amgen, with a leading Phase III program in Gastroesophageal (GE) Junction Carcinomas. According...